Time course of histological progression in primary sclerosing cholangitis

被引:49
作者
Angulo, P
Larson, DR
Therneau, TM
LaRusso, NF
Batts, KP
Lindor, KD
机构
[1] Mayo Clin & Mayo Fdn, Div Gastroenterol & Hepatol, Dept Hlth Sci Res, Rochester, MN 55905 USA
[2] Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Lab Med & Pathol, Rochester, MN USA
关键词
D O I
10.1111/j.1572-0241.1999.01543.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
OBJECTIVE: The aim of this study was to determine the time course over which patients with primary sclerosing cholangitis (PSC) progress through the histological stages of the disease. METHODS: One hundred seven patients with PSC who had at least two liver biopsies were identified. The stage information from two consecutive biopsies formed one observation and a continuous time Markov model was used to describe the rate of progression between biopsies. RESULTS: Three hundred seven liver biopsies were performed in the 107 patients giving a total of 200 observations. At 1 yr, 42% of patients in stage II disease progress, 66% at 2 vr, and 93% at 5 yr; whereas 14% of patients in stage III progress at 1 yr, 25% at 2 yr, and 52% at 5 yr. The frequency of progression of stage I disease could not be determined because of the small number of patients in stage I. Regression of histological stage was observed in 30 of 200 total observations (15%), and in 30 of 85 observations (35%) in which there was a change in stage. CONCLUSIONS: These data regarding histological progression in PSC may be potentially helpful in determining the number of patients and length of time necessary to appreciate a treatment effect in clinical trials. However, the high degree of sampling variability in PSC may restrict the usefulness of serial liver biopsies as a means of evaluating treatment efficacy. (C) 1999 by Am. Cell. of Gastroenterology.
引用
收藏
页码:3310 / 3313
页数:4
相关论文
共 19 条
[1]  
AADLAND E, 1987, SCAND J GASTROENTERO, V22, P655, DOI 10.3109/00365528709011139
[2]   Primary sclerosing cholangitis [J].
Angulo, P ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (01) :325-332
[3]   URSODEOXYCHOLIC ACID FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS - A PLACEBO-CONTROLLED TRIAL [J].
BEUERS, U ;
SPENGLER, U ;
KRUIS, W ;
AYDEMIR, U ;
WIEBECKE, B ;
HELDWEIN, W ;
WEINZIERL, M ;
PAPE, GR ;
SAUERBRUCH, T ;
PAUMGARTNER, G .
HEPATOLOGY, 1992, 16 (03) :707-714
[4]  
BHARUCHAREID AT, 1960, ELEMENTS THEORY MARK, P3
[5]   Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis [J].
Broome, U ;
Olsson, R ;
Loof, L ;
Bodemar, G ;
Hultcrantz, R ;
Danielsson, A ;
Prytz, H ;
SandbergGertzen, H ;
Wallerstedt, S ;
Lindberg, G .
GUT, 1996, 38 (04) :610-615
[6]  
DeMaria N, 1996, HEPATO-GASTROENTEROL, V43, P1472
[7]   PRIMARY SCLEROSING CHOLANGITIS - REFINEMENT AND VALIDATION OF SURVIVAL MODELS [J].
DICKSON, ER ;
MURTAUGH, PA ;
WIESNER, RH ;
GRAMBSCH, PM ;
FLEMING, TR ;
LUDWIG, J ;
LARUSSO, NF ;
MALINCHOC, M ;
CHAPMAN, RW ;
KAPLAN, MM ;
MADDREY, WC ;
WILLIAMS, R ;
FARRANT, M ;
LANGWORTHY, A .
GASTROENTEROLOGY, 1992, 103 (06) :1893-1901
[8]   NATURAL-HISTORY AND PROGNOSTIC VARIABLES IN PRIMARY SCLEROSING CHOLANGITIS [J].
FARRANT, JM ;
HAYLLAR, KM ;
WILKINSON, ML ;
KARANI, J ;
PORTMANN, BC ;
WESTABY, D ;
WILLIAMS, R .
GASTROENTEROLOGY, 1991, 100 (06) :1710-1717
[9]   ASYMPTOMATIC PRIMARY SCLEROSING CHOLANGITIS TREATED WITH URSODEOXYCHOLIC ACID [J].
HAYASHI, H ;
HIGUCHI, T ;
ICHIMIYA, H ;
HISHIDA, N ;
SAKAMOTO, N .
GASTROENTEROLOGY, 1990, 99 (02) :533-535
[10]  
Kim W. R., 1997, Hepatology, V26, p362A